Inibidores seletivos da cicloxigenase-2 (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "Inibidores seletivos da cicloxigenase-2" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
1st place
1st place
18th place
51st place
1,427th place
4,228th place
7th place
14th place
3rd place
6th place
1,684th place
1,095th place
7,827th place
4,994th place
163rd place
204th place
low place
low place
low place
low place
274th place
339th place
5th place
5th place
books.google.com
- Page CP, Curtis MJ, Sutter M, Walker M, Hoffman B (1998). Farmacología integrada (em espanhol). [S.l.]: Elsevier España. ISBN 84-8174-340-2 – via Google Books
cancer.gov
- «COX-2 Inhibitors and Cancer». Fact Sheet. United States National Cancer Institute. Cópia arquivada em 9 de maio de 2008
doi.org
dx.doi.org
- Lipfert P, Seitz R, Arndt JO (Fevereiro de 1987). «Studies of local anesthetic action on natural spike activity in the aortic nerve of cats». Ovid Technologies (Wolters Kluwer Health). Anesthesiology. 66 (2): 210–213. PMID 3813081. doi:10.1097/00000542-198702000-00016
. Os anti-inflamatórios não esteroides (AINE) são inibidores competitivos da ciclooxigenase (COX), a enzima que medeia a bioconversão do ácido araquidônico em prostaglandinas (PGs) inflamatórias.
- Hinz B, Cheremina O, Brune K (Fevereiro de 2008). «Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man». FASEB Journal. 22 (2): 383–90. PMID 17884974. doi:10.1096/fj.07-8506com
- Tirunagari SK, Derry S, Moore RA, McQuay HJ (Julho de 2009). «Single dose oral etodolac for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 2019 (3): CD007357. PMC 4164827. PMID 19588426. doi:10.1002/14651858.CD007357.pub2
- Bulley S, Derry S, Moore RA, McQuay HJ (Outubro de 2009). «Single dose oral rofecoxib for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 2009 (4): CD004604. PMC 4171390. PMID 19821329. doi:10.1002/14651858.CD004604.pub3
- Clarke R, Derry S, Moore RA (Maio de 2014). «Single dose oral etoricoxib for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 2019 (5): CD004309. PMC 6485336. PMID 24809657. doi:10.1002/14651858.CD004309.pub4
- Derry S, Moore RA (Outubro de 2013). «Single dose oral celecoxib for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 10 (10): CD004233. PMC 4161494. PMID 24150982. doi:10.1002/14651858.CD004233.pub4
- van Durme CM, Wechalekar MD, Landewé RB, Pardo Pardo J, Cyril S, van der Heijde D, Buchbinder R (Dezembro de 2021). «Non-steroidal anti-inflammatory drugs for acute gout». The Cochrane Database of Systematic Reviews. 2021 (12): CD010120. PMC 8656463. PMID 34882311. doi:10.1002/14651858.CD010120.pub3
- van Durme CM, Wechalekar MD, Landewé RB (Junho de 2015). «Nonsteroidal anti-inflammatory drugs for treatment of acute gout». JAMA. 313 (22): 2276–2277. PMID 26057289. doi:10.1001/jama.2015.1881
- Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (Março de 2009). «The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment». Carcinogenesis. 30 (3): 377–386. PMID 19136477. doi:10.1093/carcin/bgp014
- Desai SJ, Prickril B, Rasooly A (Abril de 2018). «Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer». Nutrition and Cancer. 70 (3): 350–375. PMC 6309701. PMID 29578814. doi:10.1080/01635581.2018.1446091
- Chow LW, Loo WT, Toi M (Outubro de 2005). «Current directions for COX-2 inhibition in breast cancer». Biomedicine & Pharmacotherapy. 59 (Suppl 2): S281–S284. PMID 16507393. doi:10.1016/S0753-3322(05)80046-0
- Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (Dezembro de 2007). «COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia». British Journal of Cancer. 97 (11): 1523–1531. PMC 2360252. PMID 17971769. doi:10.1038/sj.bjc.6604057
- Sethi R, Gómez-Coronado N, Walker AJ, Robertson OD, Agustini B, Berk M, Dodd S (4 de setembro de 2019). «Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders». Frontiers in Psychiatry. 10. 605 páginas. PMC 6738329. PMID 31551825. doi:10.3389/fpsyt.2019.00605
- Schönthal AH (Dezembro de 2007). «Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy». British Journal of Cancer. 97 (11): 1465–1468. PMC 2360267. PMID 17955049. doi:10.1038/sj.bjc.6604049
- Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (Maio de 2008). «COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro». Molecular Cancer. 7. 38 páginas. PMC 2396175. PMID 18485224. doi:10.1186/1476-4598-7-38
- Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (Dezembro de 2002). «Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents». Journal of the National Cancer Institute. 94 (23): 1745–1757. PMID 12464646. doi:10.1093/jnci/94.23.1745
- Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (Fevereiro de 2008). «Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs». Expert Opinion on Investigational Drugs. 17 (2): 197–208. PMID 18230053. doi:10.1517/13543784.17.2.197
- Schönthal AH (Abril de 2006). «Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy». Neurosurgical Focus. 20 (4): E21. PMID 16709027. doi:10.3171/foc.2006.20.4.14
- Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, et al. (Dezembro de 2005). «Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib». Blood. 106 (13): 4330–4338. PMID 16123214. doi:10.1182/blood-2005-07-2819
- Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, et al. (Abril de 2007). «Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib». Molecular Cancer Therapeutics. 6 (4): 1262–1275. PMID 17431104. doi:10.1158/1535-7163.MCT-06-0629
- Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (Maio de 2005). «Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo». Cancer Biology & Therapy. 4 (5): 571–582. PMID 15846081. doi:10.4161/cbt.4.5.1699
- Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (Março de 2007). «Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association». Circulation. 115 (12): 1634–1642. PMID 17325246. doi:10.1161/CIRCULATIONAHA.106.181424
- Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (Junho de 2006). «Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials». BMJ. 332 (7553): 1302–1308. PMC 1473048. PMID 16740558. doi:10.1136/bmj.332.7553.1302
- Cannon CP, Cannon PJ (Junho de 2012). «Physiology. COX-2 inhibitors and cardiovascular risk». Science. 336 (6087): 1386–1387. Bibcode:2012Sci...336.1386C. PMID 22700906. doi:10.1126/science.1224398
- Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (Abril de 1991). «Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing». Proceedings of the National Academy of Sciences of the United States of America. 88 (7): 2692–2696. Bibcode:1991PNAS...88.2692X. PMC 51304. PMID 1849272. doi:10.1073/pnas.88.7.2692
- Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (Julho de 1991). «TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue». The Journal of Biological Chemistry. 266 (20): 12866–12872. PMID 1712772. doi:10.1016/S0021-9258(18)98774-0
- Ahmadi, Mohsen; Bekeschus, Sander; Weltmann, Klaus-Dieter; von Woedtke, Thomas; Wende, Kristian (2022). «Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors». RSC Medicinal Chemistry. 13 (5): 471–496. PMC 9132194. PMID 35685617. doi:10.1039/D1MD00280E
- Awtry EH, Loscalzo J (Março de 2000). «Aspirin». Circulation. 101 (10): 1206–1218. PMID 10715270. doi:10.1161/01.cir.101.10.1206
- Marret E, Elia N, Dahl JB, McQuay HJ, Møiniche S, Moore RA, et al. (Dezembro de 2009). «Susceptibility to fraud in systematic reviews: lessons from the Reuben case». Anesthesiology. 111 (6): 1279–1289. PMID 19934873. doi:10.1097/ALN.0b013e3181c14c3d
- White PF, Rosow CE, Shafer SL (Março de 2011). «The Scott Reuben saga: one last retraction». Anesthesia and Analgesia. 112 (3): 512–515. PMID 21350225. doi:10.1213/ANE.0b013e318209736f
- Halpern, Georges M (setembro de 2005). «COX-2 inhibitors: a story of greed, deception and death». InflammoPharmacology (em inglês) (4): 419–425. ISSN 0925-4692. doi:10.1163/156856005774415574. Consultado em 10 de janeiro de 2024
- Smith R (Agosto de 2006). «Lapses at the new England journal of medicine». Journal of the Royal Society of Medicine. 99 (8): 380–382. PMC 1533509. PMID 16893926. doi:10.1177/014107680609900802
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. (Novembro de 2000). «Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group». New England Journal of Medicine. The New England Journal of Medicine. 343 (21): 1520–8, 2 p following 1528. PMID 11087881. doi:10.1056/NEJM200011233432103
- Curfman GD, Morrissey S, Drazen JM (Dezembro de 2005). «Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8». The New England Journal of Medicine. 353 (26): 2813–2814. PMID 16339408. doi:10.1056/NEJMe058314
- Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, et al. (Outubro de 2004). «Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo». Cancer Research. 64 (20): 7210–7215. PMID 15492235. doi:10.1158/0008-5472.CAN-04-1795
- Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS (Março de 2007). «Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma». Oncogene. 26 (13): 1920–1931. PMID 16983334. doi:10.1038/sj.onc.1209981
europa.eu
ema.europa.eu
- «Public data from Article 57 database». European Medicines Agency. 17 de setembro de 2018. Consultado em 25 de junho de 2021. Cópia arquivada em 2 de outubro de 2018
fda.gov
- «FDA Approves Celebrex for New Indication». U.S. Food and Drug Administration. 23 de dezembro de 1999. Consultado em 8 de maio de 2008. Cópia arquivada em 10 de maio de 2008
- «NAME OF DRUG: Rofecoxib (MK-0966) : Memorandum» (PDF). Fda.gov. Consultado em 4 de janeiro de 2015
- Abrams TW (17 de setembro de 2001). «Warning Letter» (PDF). Division of Drug Marketing, Advertising, and Communications (nenhum). Carta para Raymond V Gilmartin (Merck & Co., Inc). U.S. Food and Drug Administration. Consultado em 4 de janeiro de 2015. Cópia arquivada (PDF) em 6 de janeiro de 2012
google.com
- [1], Young DA, O'Banion MK, Winn VD
harvard.edu
ui.adsabs.harvard.edu
- Cannon CP, Cannon PJ (Junho de 2012). «Physiology. COX-2 inhibitors and cardiovascular risk». Science. 336 (6087): 1386–1387. Bibcode:2012Sci...336.1386C. PMID 22700906. doi:10.1126/science.1224398
- Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (Abril de 1991). «Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing». Proceedings of the National Academy of Sciences of the United States of America. 88 (7): 2692–2696. Bibcode:1991PNAS...88.2692X. PMC 51304. PMID 1849272. doi:10.1073/pnas.88.7.2692
hodgsonruss.com
- Kadle R, ed. (2010). «Reach-Through Claims Declared Invalid». Publications: Hodgson Russ LLP. Consultado em 23 de maio de 2015. Cópia arquivada em 1 de agosto de 2010
kayescholer.com
- University Of Rochester, Plaintiff-Appellant, V. G.D. Searle & Co., Inc., Monsanto Company, Pharmacia Corporation, and Pfizer Inc., Defendants-Appellees., 358 F.3d 916; 2004 U.S. App. LEXIS 2458; 69 U.S.P.Q.2D (BNA) 1886 917 (United States Court of Appeals for the Federal Circuit 13 de fevereiro de 2004) (“A Universidade de Rochester ("Rochester") recorre da decisão do Tribunal Distrital dos Estados Unidos para o Distrito Oeste de Nova York, que concedeu julgamento sumário de que a Patente 6.048.850 dos Estados Unidos é inválida. Univ. of Rochester v. G.D. Searle & Co., 249 F. Supp. 2d 216 (W.D.N.Y. 2003). Como concluímos que o tribunal não errou ao considerar a patente '850 inválida por não cumprir o requisito de descrição escrita do 35 U.S.C. § 112, P 1, e ao conceder o julgamento sumário com base nesse fundamento, afirmamos.”).
nih.gov
ncbi.nlm.nih.gov
- Lipfert P, Seitz R, Arndt JO (Fevereiro de 1987). «Studies of local anesthetic action on natural spike activity in the aortic nerve of cats». Ovid Technologies (Wolters Kluwer Health). Anesthesiology. 66 (2): 210–213. PMID 3813081. doi:10.1097/00000542-198702000-00016.
Os anti-inflamatórios não esteroides (AINE) são inibidores competitivos da ciclooxigenase (COX), a enzima que medeia a bioconversão do ácido araquidônico em prostaglandinas (PGs) inflamatórias.
- Hinz B, Cheremina O, Brune K (Fevereiro de 2008). «Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man». FASEB Journal. 22 (2): 383–90. PMID 17884974. doi:10.1096/fj.07-8506com
- Tirunagari SK, Derry S, Moore RA, McQuay HJ (Julho de 2009). «Single dose oral etodolac for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 2019 (3): CD007357. PMC 4164827. PMID 19588426. doi:10.1002/14651858.CD007357.pub2
- Bulley S, Derry S, Moore RA, McQuay HJ (Outubro de 2009). «Single dose oral rofecoxib for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 2009 (4): CD004604. PMC 4171390. PMID 19821329. doi:10.1002/14651858.CD004604.pub3
- Clarke R, Derry S, Moore RA (Maio de 2014). «Single dose oral etoricoxib for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 2019 (5): CD004309. PMC 6485336. PMID 24809657. doi:10.1002/14651858.CD004309.pub4
- Derry S, Moore RA (Outubro de 2013). «Single dose oral celecoxib for acute postoperative pain in adults». The Cochrane Database of Systematic Reviews. 10 (10): CD004233. PMC 4161494. PMID 24150982. doi:10.1002/14651858.CD004233.pub4
- van Durme CM, Wechalekar MD, Landewé RB, Pardo Pardo J, Cyril S, van der Heijde D, Buchbinder R (Dezembro de 2021). «Non-steroidal anti-inflammatory drugs for acute gout». The Cochrane Database of Systematic Reviews. 2021 (12): CD010120. PMC 8656463. PMID 34882311. doi:10.1002/14651858.CD010120.pub3
- van Durme CM, Wechalekar MD, Landewé RB (Junho de 2015). «Nonsteroidal anti-inflammatory drugs for treatment of acute gout». JAMA. 313 (22): 2276–2277. PMID 26057289. doi:10.1001/jama.2015.1881
- Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (Março de 2009). «The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment». Carcinogenesis. 30 (3): 377–386. PMID 19136477. doi:10.1093/carcin/bgp014
- Desai SJ, Prickril B, Rasooly A (Abril de 2018). «Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer». Nutrition and Cancer. 70 (3): 350–375. PMC 6309701. PMID 29578814. doi:10.1080/01635581.2018.1446091
- Chow LW, Loo WT, Toi M (Outubro de 2005). «Current directions for COX-2 inhibition in breast cancer». Biomedicine & Pharmacotherapy. 59 (Suppl 2): S281–S284. PMID 16507393. doi:10.1016/S0753-3322(05)80046-0
- Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (Dezembro de 2007). «COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia». British Journal of Cancer. 97 (11): 1523–1531. PMC 2360252. PMID 17971769. doi:10.1038/sj.bjc.6604057
- Sethi R, Gómez-Coronado N, Walker AJ, Robertson OD, Agustini B, Berk M, Dodd S (4 de setembro de 2019). «Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders». Frontiers in Psychiatry. 10. 605 páginas. PMC 6738329. PMID 31551825. doi:10.3389/fpsyt.2019.00605
- Müller N (Janeiro de 2010). «COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence». Current Opinion in Investigational Drugs. 11 (1): 31–42. PMID 20047157
- Schönthal AH (Dezembro de 2007). «Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy». British Journal of Cancer. 97 (11): 1465–1468. PMC 2360267. PMID 17955049. doi:10.1038/sj.bjc.6604049
- Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (Maio de 2008). «COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro». Molecular Cancer. 7. 38 páginas. PMC 2396175. PMID 18485224. doi:10.1186/1476-4598-7-38
- Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (Dezembro de 2002). «Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents». Journal of the National Cancer Institute. 94 (23): 1745–1757. PMID 12464646. doi:10.1093/jnci/94.23.1745
- Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (Fevereiro de 2008). «Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs». Expert Opinion on Investigational Drugs. 17 (2): 197–208. PMID 18230053. doi:10.1517/13543784.17.2.197
- Schönthal AH (Abril de 2006). «Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy». Neurosurgical Focus. 20 (4): E21. PMID 16709027. doi:10.3171/foc.2006.20.4.14
- Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, et al. (Dezembro de 2005). «Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib». Blood. 106 (13): 4330–4338. PMID 16123214. doi:10.1182/blood-2005-07-2819
- Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, et al. (Abril de 2007). «Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib». Molecular Cancer Therapeutics. 6 (4): 1262–1275. PMID 17431104. doi:10.1158/1535-7163.MCT-06-0629
- Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (Maio de 2005). «Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo». Cancer Biology & Therapy. 4 (5): 571–582. PMID 15846081. doi:10.4161/cbt.4.5.1699
- Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (Março de 2007). «Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association». Circulation. 115 (12): 1634–1642. PMID 17325246. doi:10.1161/CIRCULATIONAHA.106.181424
- Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (Junho de 2006). «Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials». BMJ. 332 (7553): 1302–1308. PMC 1473048. PMID 16740558. doi:10.1136/bmj.332.7553.1302
- Cannon CP, Cannon PJ (Junho de 2012). «Physiology. COX-2 inhibitors and cardiovascular risk». Science. 336 (6087): 1386–1387. Bibcode:2012Sci...336.1386C. PMID 22700906. doi:10.1126/science.1224398
- Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (Abril de 1991). «Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing». Proceedings of the National Academy of Sciences of the United States of America. 88 (7): 2692–2696. Bibcode:1991PNAS...88.2692X. PMC 51304. PMID 1849272. doi:10.1073/pnas.88.7.2692
- Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (Julho de 1991). «TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue». The Journal of Biological Chemistry. 266 (20): 12866–12872. PMID 1712772. doi:10.1016/S0021-9258(18)98774-0
- Ahmadi, Mohsen; Bekeschus, Sander; Weltmann, Klaus-Dieter; von Woedtke, Thomas; Wende, Kristian (2022). «Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors». RSC Medicinal Chemistry. 13 (5): 471–496. PMC 9132194. PMID 35685617. doi:10.1039/D1MD00280E
- Awtry EH, Loscalzo J (Março de 2000). «Aspirin». Circulation. 101 (10): 1206–1218. PMID 10715270. doi:10.1161/01.cir.101.10.1206
- Marret E, Elia N, Dahl JB, McQuay HJ, Møiniche S, Moore RA, et al. (Dezembro de 2009). «Susceptibility to fraud in systematic reviews: lessons from the Reuben case». Anesthesiology. 111 (6): 1279–1289. PMID 19934873. doi:10.1097/ALN.0b013e3181c14c3d
- White PF, Rosow CE, Shafer SL (Março de 2011). «The Scott Reuben saga: one last retraction». Anesthesia and Analgesia. 112 (3): 512–515. PMID 21350225. doi:10.1213/ANE.0b013e318209736f
- Smith R (Agosto de 2006). «Lapses at the new England journal of medicine». Journal of the Royal Society of Medicine. 99 (8): 380–382. PMC 1533509. PMID 16893926. doi:10.1177/014107680609900802
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. (Novembro de 2000). «Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group». New England Journal of Medicine. The New England Journal of Medicine. 343 (21): 1520–8, 2 p following 1528. PMID 11087881. doi:10.1056/NEJM200011233432103
- Curfman GD, Morrissey S, Drazen JM (Dezembro de 2005). «Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8». The New England Journal of Medicine. 353 (26): 2813–2814. PMID 16339408. doi:10.1056/NEJMe058314
- Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, et al. (Outubro de 2004). «Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo». Cancer Research. 64 (20): 7210–7215. PMID 15492235. doi:10.1158/0008-5472.CAN-04-1795
- Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS (Março de 2007). «Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma». Oncogene. 26 (13): 1920–1931. PMID 16983334. doi:10.1038/sj.onc.1209981
nytimes.com
- «Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex». The New York Times. Associated Press. 1 de maio de 2012
- «Celebrex Is Found to Be No Riskier for Hearts Than Other Pain Drugs». 13 de novembro de 2016. Consultado em 10 de janeiro de 2024
sciam.com
- Borrell B (10 de março de 2009). «A Medical Madoff: Anesthesiologist Faked Data in 21 Studies». Scientific American
sltrib.com
- Harvey T (21 de setembro de 2010). «BYU spices up Celebrex lawsuit against Pfizer». The Salt Lake Tribune. Consultado em 28 de fevereiro de 2011
- Harvey T (1º de maio de 2012). «Pfizer, BYU settle Celebrex lawsuit for $450M». The Salt Lake Tribune
springer.com
link.springer.com
- Halpern, Georges M (setembro de 2005). «COX-2 inhibitors: a story of greed, deception and death». InflammoPharmacology (em inglês) (4): 419–425. ISSN 0925-4692. doi:10.1163/156856005774415574. Consultado em 10 de janeiro de 2024
the-scientist.com
- Yajnik J (27 de outubro de 2006). «University sues Pfizer over COX-2 research». The Scientist. Consultado em 11 de novembro de 2010. Cópia arquivada em 3 de fevereiro de 2009
web.archive.org
- «Public data from Article 57 database». European Medicines Agency. 17 de setembro de 2018. Consultado em 25 de junho de 2021. Cópia arquivada em 2 de outubro de 2018
- «COX-2 Inhibitors and Cancer». Fact Sheet. United States National Cancer Institute. Cópia arquivada em 9 de maio de 2008
- «FDA Approves Celebrex for New Indication». U.S. Food and Drug Administration. 23 de dezembro de 1999. Consultado em 8 de maio de 2008. Cópia arquivada em 10 de maio de 2008
- Yajnik J (27 de outubro de 2006). «University sues Pfizer over COX-2 research». The Scientist. Consultado em 11 de novembro de 2010. Cópia arquivada em 3 de fevereiro de 2009
- Kadle R, ed. (2010). «Reach-Through Claims Declared Invalid». Publications: Hodgson Russ LLP. Consultado em 23 de maio de 2015. Cópia arquivada em 1 de agosto de 2010
- Abrams TW (17 de setembro de 2001). «Warning Letter» (PDF). Division of Drug Marketing, Advertising, and Communications (nenhum). Carta para Raymond V Gilmartin (Merck & Co., Inc). U.S. Food and Drug Administration. Consultado em 4 de janeiro de 2015. Cópia arquivada (PDF) em 6 de janeiro de 2012
worldcat.org
- Halpern, Georges M (setembro de 2005). «COX-2 inhibitors: a story of greed, deception and death». InflammoPharmacology (em inglês) (4): 419–425. ISSN 0925-4692. doi:10.1163/156856005774415574. Consultado em 10 de janeiro de 2024